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Abstract 
Background: Rare nucleated CD45 negative cells in peripheral blood may be malignant such as circulating tumor 
cells. Untouched isolation thereof by depletion of normal is favored yet still technological challenging. We optimized 
and evaluated a novel magnetic bead-based negative selection approach for enhanced enrichment of rare peripheral 
blood nucleated CD45 negative cells and investigated the problem of rare cell contamination during phlebotomy.
Methods: Firstly, the performance of the magnetic cell separation system was assessed using leukocytes and culti-
vated fibroblast cells in regard to depletion efficiency and the loss of cells of interest. Secondly, a negative selection 
assay was optimized for high performance, simplicity and cost efficiency. The negative selection assay consisted of; a 
RBC lysis step, two depletion cycles comprising direct magnetically labelling of leukocytes using anti-CD45 magnetic 
beads followed by magnetic capture of leukocytes using a duopole permanent magnet. Thirdly, assay evaluation was 
aligned to conditions of rare cell frequencies and comprised cell spike recovery, cell viability and proliferation, and 
CD45 negative cell detection. Additionally, the problem of CD45 negative cell contamination during phlebotomy was 
investigated.
Results: The depletion factor and recovery of the negative selection assay measured at most 1600-fold and 96%, 
respectively, leaving at best 1.5 × 104 leukocytes unseparated and took 35 min. The cell viability was negatively 
affected by chemical RBC lysis. Proliferation of 100 spiked ovarian cancer cells in culture measured 37% against a posi-
tive control. Healthy donor testing revealed findings of nucleated CD45 negative cells ranging from 1 to 22  
cells /2.5 × 107 leukocytes or 3.5 mL whole blood in 89% (23/26) of the samples.
Conclusion: Our assay facilitates high performance at shortest assay time. The enrichment assay itself causes minor 
harm to cells and allows proliferation. Our findings suggest that rare cell contamination is unavoidable. An unex-
pected high variety of CD45 negative cells have been detected. It is hypothesized that a rare cell profile may translate 
into tumor marker independent screening.
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Background
Peripheral blood nucleated cells lacking the cell mem-
brane receptor tyrosine phosphatase CD45 (CD45neg 
cells) are rare events and of interest in biomedical 
research. Focus of investigation has been stem and pro-
genitor cells [1, 2], fetal and adult nucleated erythrocytes 
[3–5], CD45 deficient leukocytes [6, 7] and circulating 
cells of endothelial, epithelial or mesenchymal origin 
[8–10]. Elevated levels of CD45neg cells are abnormal 
to the peripheral blood cell spectrum and may represent 
pathological conditions such as autoimmunity, immune 
deficiency and hematologic, cardio-vascular or other 
malignancies [11–15]. In oncology, nucleated CD45neg 
cells of epithelial or mesenchymal type are in suspicion 
of being malignant in the setting of confirmed cancer 
cases, and are believed to have originated from a primary 
or secondary tumour, hence are referred to as circulating 
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CTC that has gained attraction as reliable diagnostic, 
predictive as well as prognostic marker and future CTC 
detection assays may be used for routine patient manage-
ment [16, 17]. Recently, efforts to culture CTCs were pur-
posed to investigate functional properties, pheno- and 
genotype, to test drug sensitivity as to support personal-
ized therapy and/or to screen and develop new drugs [18, 
19].
In general, investigations on CD45neg cells may require 
pre-enrichment at best selective enrichment. In oncology, 
numerous methods have been proposed for the enrich-
ment of CTCs, yet still do not meet much needed quality 
[20–22]. Particular interest is amounting in assays capa-
ble of enriching exclusively CD45neg CTCs and is done 
by the depletion of at best all nucleated CD45 positive 
cells [23–25]. Abnormal cells are then made detectable 
amongst residual CD45 positive and normal CD45neg 
cells. The indirect isolation strategy carries no bias in 
phenotype or physical characteristics, yields untouched 
cells ideal for culture, allows multiple marker analysis and 
further downstream selection and gives rise to maximal 
yield of the cells of interest. The so called negative selec-
tion assays mostly employed immuno-magnetic bead 
separation technology [23, 26]. However, in praxis, low 
purities must be condoned due to relative high amounts 
of unseparated CD45 positive cells and a considerable 
loss of cells of interest [23, 27, 28]. Therefore, optimi-
zation may be required in demand of high performing 
assays. Few reports exist employing magnetic bead-based 
negative selection as sole enrichment step of CTCs and 
even fewer to focus on method optimization [26, 27, 29, 
30]. Apparently, most optimization efforts aimed at the 
increment of leukocyte depletion by means of technolog-
ical advancements in the magnetic capture technology. 
Commercial and in-house systems such as high gradient 
magnetic columns (Macs, PowerMag), quadrupole flow 
or microfluidic systems have been presented [27, 29, 30]. 
Meanwhile, a 1000-fold depletion of leukocytes is within 
range of possibility, yet must be considered as high. How-
ever, such solutions are complex when compared with 
the idea of simple magnetic separation in a plastic tube 
and in presence of a permanent magnet. Besides com-
plexity and related disadvantages, previous capture sys-
tems require greater effort involving sterile preparations. 
Furthermore, assay quality criteria such as loss of cells of 
interest, the number of centrifugation steps, and assay 
time in general still have potential for improvements.
This study was primarily conducted to provide further 
advancement in rare cell enrichment technology with 
the following goals; (1) to selectively enrich nucleated 
CD45neg cells at high level based solely on magnetic bead 
technology, (2) to simplify the step of magnetic cell cap-
ture, (3) to reduce assay time as to reduce cell stress and 
foster cell preservation, (4) to minimize the loss in cells of 
interest and ultimately, (5) to benchmark the enrichment 
assay by detecting CD45neg cells from peripheral blood 
(PB). Technological advancement was made possible by a 
novel magnetic labelling method. The so called dynamic 
magnetic labelling method yields higher magnetically 
susceptible target cells (leukocytes) within shorter time 
when compared to mixing or keeping at rest, which then 
allows a relative simple magnetic capture system, reduces 
total assay time and expense of costly magnetic beads. 
This study presents a complete evaluation of the tech-
nical aspects of our negative selection assay including 
leukocyte depletion factor, cell recovery, cell viability as 
well as proliferative capability and the feasibility to enrich 
rare CD45neg cells from healthy donor PB. To detect any 
CD45neg cell, the enrichment assay was paired with two-
colour fluorescence microscopy upholding the principle 
of negative selection based on unspecific cell staining by 
acridine orange fluorescent dye staining and CD45 posi-
tivity exclusion. We employed this largely unbiased isola-
tion/detection approach to investigate the open question 
of false positive CTC identification by CD45neg cell 
contamination, which is believed to be incurred during 
phlebotomy.
To our knowledge, we are first to report negative selec-
tion assay enhancement by means of improvements on 
magnetic labelling. Major technical improvements have 
been achieved particularly in loss of cells of interest yield-
ing near complete recovery of cell spikes and in enrich-
ment assay time requiring 35 min. We detected a so far 
unreported diversity of CD45neg cells in healthy donor 
PB, which is considered to reflect the high selectivity of 
our isolation assay. Our findings did not support the idea 
of evading cell contamination such as epidermal cells 
by discarding the initial blood flow during phlebotomy. 
Moreover, this work has led us to the concept of pan-
CD45neg cell profiling, which we believe could trans-




Blood samples were obtained from two sources: (1) 
buffy coats discarded from the routine blood bank pro-
cessing at the Phramongkutklao Hospital, Bangkok, 
and (2) PB collected from volunteer healthy donors in 
both cases using standard 21G’ butterfly needle set. 
PB from healthy donors was taken by venous puncture 
collecting in total 12–14  mL in green-top BD Vacu-
tainer blood collection tubes containing sodium hepa-
rin. Contamination by dermal cells during phlebotomy 
is currently assumed to occur and to be avoided by 
discharging the initial blood flow. To investigate the 
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validity of the assumption, donations of fresh blood 
were further divided into a discharge sample compris-
ing the initial 6 mL of blood flow and a so called clean 
sample containing the subsequent 6–8  mL of blood. 
The resulting three blood sample types; buffy coat, dis-
charge and clean sample were investigated separately 
for content of CD45neg cells. Other than the evaluation 
of CD45neg cell content processing both PB discharge 
and clean samples at earliest 1 h and at latest 6 h after 
blood collection, PB was also used occasionally in opti-
mization experiments as to compare results with buffy 
coat at most after 48  h and storage at room tempera-
ture. Buffy coats were stored at 4  °C and processed at 
most 48  h after collection. Buffy coats served in assay 
optimization experiments as source of leukocytes and 
in evaluation experiments as spiking medium. The study 
protocol was undertaken as approved by the institu-
tional review board/independent ethics committee of 
Mahidol University. Informed consent was sought from 
blood donors at each time.
RBC lysis
Standard chemical lysis buffer treatment was applied to 
remove red blood cells (RBC) (154 mM NH4Cl, 10 mM 
NaHCO3, 1  mM EDTA) adjusting the blood sample to 
lysis buffer ratio to 1:10 for buffy coat and 1:25 for PB. 
The cell suspension was incubated at 4  °C for a maxi-
mum of 5  min and subsequently centrifuged at 300×g 
for another 5  min. The cell pellet was resuspended in 
10 mL PBS, supplemented with 0.5% bovine serum albu-
min and washed by centrifugation at 200×g for 10 min. 
The final cell pellet of nucleated cells containing contami-
nations of platelets and RBCs was resuspended in 100 µL 
Gibco® Advanced RPMI 1640 and kept at 4 °C until use. 
The cell numbers of nucleated cells were determined by 
hemocytometer (Neubauer) and subjected to experimen-
tation within 1 h.
Model CTCs
The cell lines L929 (fibroblasts derived from subcutane-
ous connective tissue) and A2780 (derived from ovar-
ian cancer) served as model CD45neg cells (mCD45neg) 
and were cultured in DMEM medium (Gibco, USA) 
and RPMI-1640 medium (Gibco, USA), respectively. 
All cell cultures were supplemented with 10% FBS and 
1% of Penicillin–Streptomycin (10,000  U/mL) (Gibco, 
USA) and incubated at 37 °C with 5% CO2 in a humidi-
fied atmosphere. Following culture, cells were harvested 
using 0.25% trypsin–EDTA into respective culture media 
and stored until use or for at most 7 days at 4 °C. Freshly 
harvested mCD45neg cells have been used in the experi-
ments to assess cell viability using trypan blue (Sigma) 
dye staining.
Assay performance evaluation
The overall assay performance was assessed by depletion 
factor, recovery, enrichment factor and magnetic bead 
efficiency. The depletion factor represents the ratio of 
CD45positive cells before depletion, denoted as Ltotal to 
the CD45 positive cell count after depletion, denoted as 
Lfinal. The recovery of spiked cells represents the ratio of 
the initial spiked number of mCD45neg cells to the count 
of mCD45neg cells after depletion. The enrichment fac-
tor can be assessed in two ways. One is the mathemati-
cal product of depletion factor and recovery, another way 
goes by the ratio of purities of the mCD45neg cells before 
and after depletion [31]. The bead efficiency represented 
the amount of separable leukocytes per µL magnetic 
bead solution.
Magnetic cell sorting
The immuno-magnetic cell separation system comprised 
steps of magnetic labelling and magnetic capture. The 
magnetic labelling step was part of the negative selec-
tion assay improvement and was based on the method of 
dynamic magnetic labelling (Fig. 1).
Magnetic capture was facilitated by a duopole per-
manent magnet, which was constructed by pairing two 
equally squared neodymium magnets (387mT) in attract-
ing configuration (overlapping of opposite poles) with a 
5 mm air gap creating a high gradient magnetic field in 
the vicinity between and around the edges of both mag-
nets. This site of highest magnetic effectiveness was in 
the air gap and used to place the incubation container 
after magnetic labelling. CD45 mouse anti-human IgG 
(clone MEM-28, Exbio, Praha) conjugated to magnetic 
nano-beads (Fluidmag-Ara, Chemicell, Berlin) have been 
used for direct magnetic labelling of leukocytes. The 
preparation of immune-magnetic beads employed the 
zero-length carbodiimide crosslinker method as previ-
ously described [32].
As part of the performance assessment and optimiza-
tion procedure of the magnetic bead system, a standard-
ized depletion experiment was set-up to determine the 
bead specificity and the efficiency of magnetic cell cap-
ture. The magnetic capture was translated into the bead 
efficiency. Hereby, 5 × 106 leukocytes and 1 × 104 fibro-
blast cells in pure solutions or mixed with leukocytes 
were incubated for 5  min in a 1.5  mL standard micro-
centrifuge plastic tube with various volumes of magnetic 
beads and adjusted to 60  µL at room temperature. The 
total assay time was kept fix at 10  min and comprised 
5  min of dynamic magnetic labelling, 1  min of washing 
and 4 min of magnetic capture. Subsequent to magnetic 
labelling, the incubated solution was mixed with 500 µL 
Gibco® Advanced RPMI 1640 and placed adjacent to the 
duopole permanent magnet at the location of the highest 
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magnetic gradient. The depletion factor and bead effi-
ciency was assessed by the leukocyte count in suspen-
sion after magnetic separation. The experiment outcome 
was the depletion factor and cell loss due to non-specific 
binding to magnetic beads.
As part of the assay evaluation, we isolated and 
detected CD45neg cells from healthy donor PB by nega-
tive selection and fluorescence microscopy. The com-
plete CD45neg cell isolation/detection assay comprised 
coarsely the following steps; RBC-lysis, first centrifuga-
tion/cell pelleting step, second centrifugation/washing 
step, first depletion cycle, third centrifugation/cell pel-
leting step, second depletion cycle, fourth centrifuga-
tion/cell pelleting step, fluorescence marker labelling, 
fifth centrifugation/washing step and finally microscopic 
analysis. In detail, nucleated cell counts were adjusted 
to 2.5  ×  107 nucleated cells after RBC lysis from ini-
tially 6  mL whole blood or 1.5  mL buffy coat. The cell 
suspension during the first depletion cycle was adjusted 
to 250  µL including 75–80  µL beads. Magnetic label-
ling and capture was performed in the same manner as 
for the standard depletion experiments however, having 
increased the washing volume to 1 mL. Gibco® Advanced 
RPMI 1640 was used for incubation, washing, pelleting 
and resuspension of cells. After the first depletion cycle, 
uncaptured cell material was pelleted at 300×g for 5 min 
and at room temperature. The resulting smaller pellet 
was resuspended in 40 µL using 20 µL of magnetic bead 
solution and a second depletion cycle followed.
Flow cytometry
Flow analysis was conducted on a flow cytometer BD 
FACSCanto II (BD Biosciences, San Jose, CA, USA). 
Cells suspensions contained at most 5  ×  104 cells and 
were stained with anti-CD45-PE (ebioscience) at 4 °C in 
40 µL Gibco® Advanced RPMI 1640 for at least 20 min. 
Cell suspensions consisted of leukocytes before and after 
depletion treatment being the negative control, fibro-
blasts as positive control, and spiked samples before and 
after depletion.
Microscopy analysis
Optimization experiments related to depletion efficiency 
employed exclusively leukocytes as obtained after RBC 
lysis. For microscopic analysis, a simple and fast method 
was chosen as to determine cell counts using acridine 
orange (AO) staining. In brief, 1 µL of AO stock solution 
(100  µg/mL) was added to various cell sample volumes 
ranging from 40 µL to 1 mL. In optimization experiments 
related to cell recovery, mCD45neg cells were stained 
prior to spiking in either buffy coats or leukocyte suspen-
sions using CSFE following the manufacturer’s protocol 
without modifications (CFSE Cell Division Tracker Kit, 
Biolegend). Samples with either AO or CSFE fluorescence 
were loaded on hemocytometer (Neubauer) and analyzed 
using a Carl Zeiss Axioscope 2 fluorescence microscope 
equipped with a FITC filter set.
In assay evaluation experiments, CD45neg cells from 
buffy coat, PB discharge and clean samples after RBC 
Fig. 1 Summary of magnetic separation method. Step 1 Mixing the beads with the cell suspension. Step 2 Subjecting the incubation container to 
continued axial rotation at around 5–30 rpm in direct vicinity of a strong permanent magnet for 1 min. Step 3 Mixing of the incubated suspension 
by continued pipetting and dispensing or vortexing. Steps 2 and 3 have been repeated 5 times. Step 4 Washing by diluting the incubated solution 
with cell-friendly buffer solution 1:1 and intensive mixing. Step 5 Placing the incubation tube into the vicinity of a strong permanent magnet for 
magnetic capture and keep at rest for at least 4 min
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lysis and leukocyte depletion were detected by two color 
fluorescence microscopy staining cells using AO fluo-
rescence dye and anti-CD45PE conjugated antibodies 
(ebioscience). In brief, 30–40  µL of cell suspension was 
incubated with 3 µL anti-CD45 conjugate solution at 4 °C 
in the dark for at least 20  min followed by AO staining 
as already described for optimization experiments and 
then washed by centrifugation at 300×g and 5 min with 
1.5 mL Gibco® Advanced RPMI 1640 and resuspended in 
30 µL. The cell suspension was then loaded dropwise at 
10–15 µL onto a microscopy slide without cover. Visuali-
zation of cell fluorescence was performed using a Nikon 
Eclipse TE2000-E inverted fluorescence microscope 
equipped with filter sets for fluorescent dyes FITC, phos-
phatidylethanolamine (PE) and Texas Red. Microscopic 
reading was done manual by visualization at 200× and 
400× magnification spotting CD45neg cells under fluo-
rescence green light emission and recording of suspicious 
cells using a Carl Zeiss Axiocam MR colour and MRGrab 
software under brightfield illumination as well as fluores-
cent light. CD45neg cells were identified as near round 
objects in sizes between 4 and 25  µm in diameter with 
clear contrast to background under brightfield visuali-
zation and appearing in AO fluorescence yet lacking PE 
fluorescence when measured against background inten-
sity. AO fluorescence leaking into the PE channel slightly 
above background intensity was identified by equal fluo-
rescence intensity distribution across the cell or higher 
intensity in the center of the cells as opposed to the ring-
like fluorescence appearance of CD45PE positive cells 
throughout the emission light spectrum from 520 till 
650 nm.
Cell recovery
The recovery rate of the isolation assay was determined 
by spiking 2, 5 and 8 CFSE stained mCD45neg cells into 
buffy coat at volumes that corresponded to 2.5  ×  107 
nucleated cells. Cells for spiking were selected from stock 
solutions by slowly drawing individual cells into a 10 µL 
plastic tip under microscopic vision at 100× magnifica-
tion and fluorescence excitation using an inverted fluo-
rescence microscope (Nikon Eclipse TE2000-E) equipped 
with FITC filter set. In brief, CSFE stained mCD45neg 
cells were diluted from stock (approx. 1 ×  105 cells/µL) 
to a final concentration of max. 5 cells/µL in one flat bot-
tom well of a 96-well plate. The tip of a 10 µL pipette was 
introduced into the well bottom. The controlled and slow 
passage of strong green fluorescent cells into the pipette 
tip was counted and visualized by adjusting the focus 
layer to the tip end position. After the aspired cell num-
ber was reached, the tip was removed from the well and 
the cells within the pipette tip were expelled directly into 
the blood sample. The spiked sample was then subjected 
to RBC lysis, magnetic labelling and capture followed by 
microscopic analysis as described in “Magnetic cell sort-
ing” section for negative selection of CD45neg cells.
Cell viability and proliferative capability
Pure suspensions of freshly harvested mCD45neg were 
adjusted to contain 5  ×  105 cells and subjected to the 
exact same procedure of the negative selection assay 
including RBC lysis as described for buffy coat samples 
(“Cell recovery” section). Trypan Blue dye staining was 
used to determine viability of the harvested cells before 
the process, after RBC lysis, after the first depletion cycle 
and after the second depletion cycle.
Cell proliferation was assessed by spiking 100 freshly 
harvested ovarian cancer cells into buffy coat contain-
ing 2.5 × 107 leukocytes. The spiked number of cells was 
determined using a hemocytometer (Neubauer). The 
same negative selection procedure was applied to the 
sample as described above yet requiring sterile prepara-
tions therefore working under laminar flow conditions 
and with sterile solutions. The resulting cell suspension 
after magnetic treatment was then diluted in 7.5  mL 
growth medium and transferred into 3 wells of a 6-well 
plate at equal volumes for culture. A positive control 
without any treatment was prepared containing the same 
starter amount of ovarian cancer cells and was subjected 
to culture under same conditions as the spiking sam-
ple. The growth medium remained unchanged until day 
7. The cell proliferation in culture of the sample and the 
positive control were analyzed by an inverted brightfield 
microscope. Proliferative activity was defined as at least 
two clearly dividing, bottom attached cells and being sig-
nificant larger than any nucleated CD45 positive cell.
Statistics
One tailed t test and correlation analysis (Micro-
soft Excel) was employed for statistical analyses of the 




The optimization of immuno-magnetic separation sys-
tem was guided by theoretical considerations about 
attainable assay performance. Scarcity of CD45neg 
cells in particular CTCs, translates into relative large 
sampling volumes and the requirement of a low limit 
of detection (LOD) measuring one cell per 1 to max. 
10 mL blood [17]. One major goal of optimization was 
to reduce costs hence, bead expense. The predetermina-
tion of the lowest possible Ltotal may appear reasonable 
in view of a relative high cell-to-bead ratio and the high 
number of target cells. Given an assumed CD45neg cell 
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frequency of 1 cell per 3 mL PB, a recovery of at least 80 
and a 90% sensitivity of analysis, we may require at least 
4.2  mL  PB or a minimal Ltotal of 2.5 ×  107 cells (aver-
age 6 ×  106/mL) to be able to detect one cell of inter-
est. Following this initial estimation, we identified and 
standardized our assay to the minimal Ltotal of 2.5 × 107 
leukocytes regardless the blood volume and aimed at a 
recovery that would support an assay LOD of 0.24 cells/
mL.
Another performance criterion is the enrichment 
factor, which is presented as the mathematical prod-
uct of cell recovery and the depletion factor or the 
ratio between purities of cells of interest before and 
after enrichment [31]. Both primary measures of per-
formance, the depletion factor and the recovery usu-
ally stand opposed to each other in magnetic bead 
separation technology, as key is the amount of beads 
per sample as well as the rate of non-specific binding. 
Depletion factors were qualified according to standard 
performance in the field ranging till 14.5 as subnormal, 
till 33.5 as normal, till 100 as high, and depletion fac-
tors beyond 100 as ultra-high depletion. Targeting a 
recovery of 80% may seem reasonable when compared 
with other works [26]. We considered Lfinal counting 
2–4  ×  104 leukocytes as tolerable interference during 
microscopic reading therefore, requiring at least 625-
fold depletion for Ltotal equal to 2.5 × 107 cells and 500-
fold enrichment.
The ease and speed of sample processing, but also 
analysis would affect the sample throughput and costs 
per test. Shortened assay time may also reduce cell stress 
thus, help to reduce cell loss and as such improve the 
LOD and likelihood of cell proliferation in culture. It is 
declared goal to limit the assay time including analysis to 
2 h. Key to speed is the dynamic magnetic labelling pro-
cedure. The performance parameters and their aspired 
values are listed in Table 1.
Magnetic separation system efficiency
We then investigated the actual performance of the 
immuno-magnetic separation system in regard to deple-
tion factor and cell loss carrying out time fixed stand-
ardized depletion experiments. We introduced bead 
efficiency as an indicator of depletion performance that 
we defined as the amount of magnetically separable 
cells/µL magnetic bead solution. This performance value 
helped us to predetermine the bead amounts required 
for attainable depletion levels at given cell amounts. The 
bead efficiency is influenced by the entire magnetic sepa-
ration system that includes the magnetic bead reactiv-
ity, the magnetic labelling method, the magnetic capture 
technology and even the functional properties of the bio-
logical system. Magnetic bead volumes were varied using 
up to 50 µL then in principle adding cells to the magnetic 
bead solution at the given yet arbitrary maximal incuba-
tion volume of 60 µL. Figure 2 shows the bead efficiency 
as a function of depletion factor and reveals that the 
magnetic separation system was able to yield a high-level 
depletion factor within 10 min.
It was wishful to be in control of the depletion level for 
the later design and optimization of the negative selec-
tion assay. We understand from the results firstly, that 
the depletion factor can be predetermined by adjusting 
the right amount of magnetic beads and secondly, that 
depleting at higher depletion levels requires significant 
more bead expense. For subnormal depletion, 1  µL of 
bead solution was enough to separate around 4.8 × 105 
leukocytes. Yet, high-level depletion required around 3 
times more bead volume to capture the same leukocyte 
amount using up almost all of the given incubation vol-
ume for the bead solution. A third observation was that 
the drop in bead efficiency with higher depletion factors 
did not follow a linear trend suggesting the elevation in 
bead efficiency with respect to the depletion level. As a 
matter of fact, the bead concentration increased as a 
Table 1 Assay performance parameters
Parameter Optimization goal Definition Dependencies
Limit of detection (LOD) 0.24 cells/mL peripheral blood Detection of at least one cell of interest 
in 4.2 mL blood or 2.5e7 total cells
Test sensitivity, recovery, Ltotal
Enrichment factor >500 Ratio between the cell-of-interest fre-
quency before and after enrichment
Depletion factor and recovery
Depletion factor >625 Ratio between the leukocyte amount 
before and after enrichment
Bead amount high
Recovery 80% Measure of target cell loss Bead amount low
Initial leukocyte amount, Ltotal 2.5 × 107 Assay start with leukocyte cell count Blood volume 3–7 mL, enrichment factor, 
cell of interest frequency,
Residual leukocytes, Lfinal 2 × 104 to 4 × 104 cells Leftover leukocytes after depletion Depletion factor
Assay time 2 h Complete assay time including isolation 
and analysis
RBC lysis quality and enrichment factor
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consequence of lesser dilution of the bead stock solu-
tion. Higher bead concentrations were shown to enhance 
magnetic labelling and consequently magnetic capture 
[33]. The highest depletion level measured 65-fold deple-
tion for this specific experiment set-up.
Besides the magnetic bead amount, the storage time of 
the blood sample was found to be of great influence on 
the system, in particular on the high depletion range. We 
tested whole blood samples aged 5, 24 and 48 h aiming 
at normal depletion and observed a significant reduction 
in bead efficiency measuring depletion factors of 25, 14.5 
and 6.7, respectively. We reasoned that dead or apoptotic 
cells would be less separable and that its amount would 
increase with blood storage time.
The cell loss due to non-specific binding of the magnetic 
beads to the cells of interest was assessed at standard 
protocol conditions using 1 × 104 fibroblast cells as pure 
suspension and spiked in leukocyte suspension (Table 2). 
The degree of non-specific binding is believed to depend 
amongst other factors on amount and concentration of 
magnetic beads and therefore, is expected to increase 
when seeking higher depletion factors. We also expected 
higher non-specific binding in pure fibroblast suspensions 
due to the significant higher bead to fibroblast cell ratio 
when compared to mixed cell suspensions. The superna-
tant after depletion was investigated for remaining fibro-
blast content and recorded in percent based on the initial 
spiked count of fibroblast cells. We observed substantial 
non-specific capture of fibroblast cells only in pure cell 
suspension and at the high depletion level. Nevertheless, 
in mixed suspension, the fibroblast loss at the high deple-
tion level was notable with around 8%. The overall perfor-
mance assessment of the cell separation system suggested 
that up to 98.4% leukocytes could be depleted without 
marked loss of cells of interest yielding a possible 58.2-
fold enrichment factor within 10 min.
Negative selection assay
The results of the performance assessment in the previ-
ous section have been used to design a negative selec-
tion assay. Depleting leukocytes at the ultra-high level 
was hardly possible, and if so at excessive expense of 
costly beads. Therefore, for larger blood sample volumes, 
the elevation of the depletion factor by means of bead 
amount did not seem practical. One observation during 
performance assessment experiments was that a consid-
erable minority of nucleated cells (data not shown) would 
not be easily separable, hence discriminating leukocytes 
into high and low reactive against the magnetic beads. 
Determined to reduce the expense of beads, the idea may 
seem plausible to employ two depletion cycles both com-
prising magnetic labelling and capture that would ini-
tially deplete the majority of highly reacting leukocytes 
yielding highest possible bead efficiency followed by the 
depletion of the fewer left-over and less reacting leuko-
cytes however, at considerable lower bead efficiency. 
Based on the records of bead efficiency (Fig.  2), we 
intended to establish and test a repeated depletion pro-
tocol for the negative selection assay as shown in Table 3.
Our previous results showed decreased bead efficiency 
in dependence of blood age (“Magnetic separation sys-
tem efficiency” section). Therefore, buffy coats as well as 
fresh blood samples were used before the resting time of 
24 and 12 h, respectively. As part of the optimization pro-
cess, cell losses along the process steps have been identi-
fied by spiking experiments using 1 × 104 fibroblast cells 
and purified leukocyte suspensions adjusted to 2.5 × 107 
cells. The cell mixture was incubated with 75–80  µL of 
magnetic bead solution in 250 µL incubation volume dur-
ing the first depletion step and with 20 µL bead suspen-
sion in maximal 40 µL during the second depletion step. 
Different incubation volumes between the two depletion 
cycles have been chosen to sustain a bead concentra-
tion that would facilitate fast bead-cell binding kinetics. 
In numerous repeats, the final depletion factor and the 
fibroblast recovery measured on average 888-fold (±395) 
and 92.8% (±3.3%), respectively and 1667-fold and 96.4% 
at best, resulting in a possible average 824-fold enrich-
ment. The bead efficiency for the 2-step procedure using 
Fig. 2 Bead efficiency. Quantitative assessment of the potential of 
the bead solution to separate targeted cells. The bead efficiency 
(±SD) was assessed in range of ×10 to ×50 depletion and meas-
ured 1.4 × 105 to 4.6 × 105 cells/µL. The trend line was assumed 
exponential
Table 2 Non-specific binding analysis









Subnormal (n = 3) 8.9 ± 0.8 0.0
Normal (n = 4) 13.4 ± 1.1 1.6 ± 1.1
High (n = 3) 36.3 ± 4.3 8.3 ± 2.3
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fresh blood not older than 12 h measured 2.63 × 105/µL 
using maximal 95 µL of bead solution. The assay time not 
including analysis measured 35  min. The performance 
of the negative selection assay was qualitatively investi-
gated by flow cytometry. Figure 3a–d depict the enrich-
ment when gated specifically for the fibroblast fraction. 
Fibroblasts stained negative for CD45PE as expected 
(Fig. 3b). The final purity of the enriched fibroblast cells 
measured 95.4% from originally 0.3% when initially gat-
ing the fibroblast population. We also observed cell selec-
tive depletion efficiency (Fig.  3e, f ). A near complete 
depletion of the monocyte and granulocyte fraction was 
achieved leaving a marked residual leukocyte amount in 
the lymphocyte fraction. This was in concordance with 
microscopy analysis showing that the majority of left-
over leukocytes are relative round and small cell as can 
Table 3 Projection of attainable negative selection assay depletion performance
Incubation Ltotal Depletion factor Lfinal Bead efficiency (cells/µL)
First depletion 2.5 × 107 20× 1.25 × 106 3.4 × 105
Second depletion 1.25 × 106 50× 2.5 × 104 1.4 × 105
Total depletion 2.5 × 107 1000× 2.5 × 104 3.0 × 105
Fig. 3 Flow cytometry of fibroblast spiking experiment. a Gated CD45PE stained fibroblast cells in red. b Plot of CD45PE stained fibroblast subpopu-
lation gated by fluorescence mode. c Purified leukocytes solution containing 2.5 × 107 normal cells and 1 × 104 fibroblast cells before depletion as 
gated in a. The subpopulation in red comprises granulocytes. The population in green comprises monocytes. d Sample after depletion as gated in a. 
The red population comprises mainly fibroblasts. e Unspiked purified leukocyte suspension gated for all cell populations before depletion. The red 
population comprises granulocytes (35%), the green population comprises monocytes (10.9%), the blue population comprises lymphocytes (32.9%) 
and the magenta population comprises debris (13.5%). f Enriched leukocyte population. The red population comprises granulocytes (1.1%), the 
green population comprises monocytes (0.9%), the blue population comprises lymphocytes (26.6%) and the magenta population comprises debris 
(50.4%)
Page 9 of 16Schreier et al. J Transl Med  (2017) 15:6 
be seen in Figs.  5 and 6. Large cells formed the minor-
ity counting only 2200 cells on average in a suspension of 
1.5–4 ×104 remaining leukocytes.
Cell recovery
Having adjusted a relative high cell spike in the preced-
ing experiments for reasons of cell loss identification and 
qualitatively analysis by flow cytometry, spiking quanti-
ties that simulate true rare cell frequencies may give a 
closer estimate on the possible LOD of the isolation/
detection assay. Therefore, we determined the recovery of 
ovarian cancer and fibroblast cells spiking 2, 5 and 8 cells 
into buffy coat. The leukocyte concentration in buffy coat 
was determined prior to spiking and the volume adjusted 
to contain 2.5  ×  107 leukocytes. Each spiking level has 
been repeated three times (Table  4). All experiments 
showed recovery of most of the cells. The two cell spikes 
were positive for both cell lines in all cases. Therefore, 
the assay may support a LOD of 0.33 cells/mL detecting 
at least 1 CD45neg cell in 1.25 × 107 total cells or 3 mL 
fresh blood.
Cell viability and proliferation
The viability or cell damage due to RBC lysis and the leu-
kocyte depletion procedure was determined by trypan 
blue dye exclusion using ovarian cancer and fibroblast 
cell lines (Fig. 4a). The assay evaluation experiments were 
carried out once using fibroblasts and twice using ovar-
ian cancer cells. The results were consistent between 
the two cell lines and suggested a slight decrease in via-
bility according to one depletion cycle by maximal 3%. 
A relative high decrease in viability of maximal 9% was 
measured after chemical lysis of RBCs. The proliferative 
activity of 100 ovarian cancer cells was tested on a con-
trol and a cancer cell spiked blood sample. Dividing cells 
or cell outgrowth (Fig. 4b) was counted as a single event. 
The control sample counted 27 such events. The ovarian 
cells undergoing the enrichment treatment proliferated 
less when compared with the positive control, counting 
10 events. The cell cultures were found to be free of bac-
terial contamination throughout the period of culture.”
Isolation/detection assay feasibility
Encouraged by the high cell recovery for lowest spik-
ing numbers and the high cell viability, we went on to 
investigate the potential of our isolation assay to enrich 
CD45neg cells from PB. Moreover, we applied the assay 
to contribute to the ongoing debate about false posi-
tive CTC identification. Since there has not been identi-
fied any marker, which is solely characteristic to CTCs 
so far, we can presume that the most conserved CTC 
selection criteria are CD45 negativity and cell nuclea-
tion in size greater 4 µm. In order to serve both purposes, 
the feasibility assessment of the enrichment assay and 
the investigation of CTC false positives, we used two-
color fluorescence microscopy for analysis based on cell 
nucleation and CD45 positivity exclusion sampling buffy 
coat, discharge and clean whole blood samples. Reader 
accuracy and linearity was assessed in side experiments 
using cell spikes across the range of 2–2000 mCD45neg 
cells in suspensions of 2 ×  104 leukocytes and followed 
by fluorescent dye staining confirming highest accu-
racy and linearity (data not shown). Naturally, most cells 
after enrichment stained positive for CD45 at varying 
fluorescence intensities and appeared typically as a ring 
(Fig. 5a). Consequently, true CD45neg cells did not show 
any fluorescence ring formation and appeared purely in 
AO fluorescence (Fig. 5b, c).
We detected CD45neg cells in 88.9% of the sam-
pled blood at frequencies from 1 to 22 cells (average 5.6 
cells/2.5 × 107 WBCs and in 58% (13/26) of the sampled 
blood exceeding 3 cells and including all three sample 
types (Table  5). Furthermore, the probability to recov-
ery zero cells measured 11.5%. It shall be reminded that 
Ltotal counting 2.5  ×  107 leukocytes was crucial to the 
sampling. The average cell concentration in whole blood 
donors measured 7.0 × 106 ± 1.5 × 106 cells hence, sam-
pling on average a blood volume of 3.6 mL. The CD45neg 
cells of interest greatly varied in size, morphology and 
AO fluorescence color and intensity. For the prevailing 
idea that cell abnormality in regard to tumor growth may 
be cell size dependent, we grouped the detected cells into 
three size categories. The sizing was referenced to the 
Table 4 Recovery of single cell spiking experiments





8 (n = 3) 7, 5 5 70.8% (62.5–87.5%)
5 (n = 3) 4, 4 4 80% (80%)
2 (n = 3) 1,1 2 66.7% (50–100%)
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average diameter of normal nucleated CD45 positive cells 
in the depleted sample found to measure 8.4 ±  1.1 µm. 
Representative images of CD45neg cells at different sizes 
are shown in Fig. 6.
Previous investigations on healthy donors revealed cell 
findings that appeared phenotypical and morphological 
similar or even identical to CTCs potentially leading to 
increased false positive identification [24, 27, 34, 35]. A 
common thought was that such cell contaminations are 
incurred during phlebotomy and are avoided by discharg-
ing the first 5–20 mL of blood [35]. We reasoned that our 
diagnostic approach would be suited to address the CTC 
research question of non-hematopoietic cell contami-
nation. Therefore, we separated the fresh blood sample 
into discharge that constitutes the first 6  mL of blood 
flow and into the clean sample containing 6 mL blood of 
the continued flow. The analysis by CD45 exclusion was 
limited to quantitatively investigation of the problem. 
According to the theory, one would expect more cells 
in particular larger cells in the discharge sample than 
in the clean blood sample and buffy coat. However, the 
cell counts between both samples were not significantly 
different (p > 0.2) counting even slightly more CD45neg 
cells on average in the clean blood sample (Table 5). This 
relationship does not change when excluding the small 
cell group from analysis. Our findings may be sensible in 
light of the blood sample resting time suggesting a nega-
tive relationship between the number of blood resting 
time and CD45neg cell count (r = −0.86). A significant 
reduction in cell counts was found for buffy coat samples 
(6 h, p < 0.18 and 24 h, p < 0.025).
The findings of relative high quantities and a great 
variety of CD45neg cells encouraged us to comprehend 
the cell count of each donor as an individual CD45neg 
profile. As it is known that CD45neg cells are indicative 
for various health problems or conditions depending on 
type, quality and quantity, the idea made sense to us to 
qualify CD45neg cell profiles as normal and abnormal, 
respectively according to averaged cell quantities. In that 
sense, three healthy fresh blood donors showed abnormal 
CD45neg cell profiles. Donors 2 and 9 were in particular 
Fig. 4 Cell viability and proliferation. a Viability assessment (±SD) of mCD45neg cells by Trypan Blue staining after each step of the negative selec-
tion assay. b Ovarian cancer cell outgrowth developing from 100 cell spike in buffy coat after negative selection procedure and 7 day culture. The 
bar represents the length of 20 µm
Fig. 5 Cell image analysis. Cells are recorded at 4 different appear-
ances from left to right; under brightfield, AO fluorescence, PE 
fluorescence and contrast enhanced (ImageJ manual brightness 
adjustment) PE fluorescence. The bars represent a length of 10 µm.  
a CD45 positive cell identification. The cell indicated by a white arrow 
shows low AO as well as ring shaped PE fluorescence. CD45 negative 
cell identification with normal (b) and high (c) AO fluorescence inten-
sity without ring formation in the light wavelength above 550 nm. 
Residual fluorescence is pronounced (b) and at noise level (c), visible 
only after contrast enhancement. The fluorescence signal is ascribed 
to AO fluorescence only
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abnormal for small CD45neg cells that were highly simi-
lar in morphology and AO fluorescence, counting at 
most 16 and 7 cells, respectively (Fig. 7a, b). The average 
small cell count per each donor was found to measure 
2.5 ± 4.2 cells (excluding donors 2 and 9, 0.9 ± 1.2 cells) 
per 2.5 × 107 nucleated cells (Table 5). Donor 9 showed 
also an abnormal profile with highest total CD45neg cell 
count detecting at most 22 cells. The average total cell 
count per each donor was found to measure 5.7  ±  2.6 
cells/2.5  ×  107 nucleated cells (Table  5). The CD45neg 
profile of donor 6 showed a highest level of large cells 
that would appear unique in morphology when com-
pared to the CD45neg cell profiles of all other blood sam-
ples counting at most 12 such cells (Fig. 7c–f).
Discussion
Magnetic bead-based negative selection assays have 
been commonly applied to isolate rare cells in particular 
CTCs [23]. Downstream applications such as cell analy-
sis, cell culture or additional enrichment steps may affect 
the enrichment assay performance requirements leading 
to differences in effort of enrichment. In CTC research, 
optical analysis mostly employed multiple marker analy-
sis, which allows a relative high leukocyte interference 
level hence, low enrichment or no enrichment at all [36]. 
When used in combination with molecular analysis that 
frequently depended on pre-amplification of nucleic 
acids, high enrichment may be beneficial to prevent 
overly false positives or unfavourable cut-off. Employing 
Table 5 CD45neg cell analysis in healthy blood samples
a Donor 2, blood condition; threefold higher platelet count, low RBC count
b Donor 6, under suspicion of abnormal cell content, followed up candidate
c Donor 9, frequent blood donor (donation of 500 mL two weeks before the test)




Small cells (4 > 6 µm) Sum of cells Blood resting 
time (h)
Buffy coat (n = 9) 1 2 1 0 3 24
2 1 0 0 1
3 2 2 0 4
4 1 0 0 1
5 2 4 0 6
6 0 0 0 0
7 4 4 2 10
8 1 1 0 2
9 0 0 0 0
Average 1.4 1.3 0.2 3
Whole blood sample: clean 
collection after 6 mL 
(n = 9)
Donor 1 0 0 3 3 6
Donor 2a 0 0 16 16 6
Donor 3 1 2 0 3 6
Donor 4 1 1 2 4 6
Donor 5 0 4 2 6 6
Donor 6b 12 1 1 14 3
Donor 7 0 1 0 1 6
Donor 8 3 3 0 6 3
Donor 9c 6 9 7 22 1
Average 2.6 2.3 3.44 8.3
Whole blood sample: dis-
charge collection of the 
first 6 mL (n = 8)
Donor 1 0 0 0 0 3
Donor 2a 1 1 8 10 3
Donor 3 3 1 0 4 3
Donor 4 1 1 3 5 3
Donor 5 N.A. N.A. N.A. N.A. 3
Donor 6b 4 0 0 4 6
Donor 7 1 1 0 2 3
Donor 8 3 2 0 5 6
Donor 9c 7 8 2 17 1
Average 2.5 1.8 1.6 5.9
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next generation sequencing methodology requires 
high enrichment effort as otherwise sampling becomes 
extremely costly. We paired our enrichment assay with 
simple two color fluorescence microscopy, denoted as 
pan-CD45neg cell isolation/detection assay following the 
principle of unbiased isolation and detection. Numerous 
nucleated cells were found to express the CD45 receptor 
at lowest levels (for example Fig.  5a) leading to tedious 
and timely microscopic reading. For that reason, leu-
kocyte interference was sought to be kept at a practical 
minimum in range of 2–4 × 104 nucleated cells and con-
sequently required ultra-high, at least 625-fold depletion.
Reports about assay development and own experience 
let us believe that the innovation in bead based negative 
selection assays requires considerable attention [26, 27, 
29, 37]. A quadrupole magnetic bead based cell separa-
tion system was specifically optimized for the purpose of 
high leukocyte depletion testing different magnetic bead 
systems [26]. High performance was reported for a proto-
col using an indirect magnetic labelling step that employs 
1 µm magnetic beads and the so called tetrameric anti-
body complexes linker system (Stemcell Technology). An 
average of 3.07 log10 depletion and maximal 84% recovery 
of melanoma cell line spikes were reported. An in-house 
magnetic separation column based system (PowerMag) 
was compared with Easymag (Stemcell Technologies) and 
was found to be superior [27]. Indirect magnetic labelling 
was used choosing a cocktail of primary antibodies reac-
tive against various leukocyte subtypes. Magnetic label-
ling and separation was repeated up to 4 times, reporting 
as high as 5.7log10 leukocyte depletion and a recovery of 
77%. Repeated cycles of negative selection have been also 
applied using a microchip separation system and direct 
magnetic labelling with anti-CD45 reactive Dynabeads 
reporting 99.83% leukocyte depletion and 32% recovery 
of colon cancer cell line spikes [30]. While most efforts of 
improvement were on costs of simplicity, assay time and 
bead expense, we intended to include these performance 
criteria into the scope of optimization. Advancement in 
assay performance was possible by employment of the 
dynamic magnetic labelling procedure. The labelling 
method was based on the agitation of magnetic beads 
during incubation by slowly rotating the incubation tube 
in the presence of a magnetic field. A 1 min rotation cycle 
Fig. 6 Images of CD45negative cells. Representative images of 
cells from different donors shown under brightfield, fluorescence 
green light and fluorescence red light. Type 1 Large round/oval cell 
with strong AO fluorescence. Type 2 Large irregular shaped cell with 
medium AO fluorescence. Type 3 Medium sized round cell with two 
distinct high AO fluorescence patches. Type 4 Medium-sized oval 
shaped cell with two distinct very low AO fluorescence nuclei. Type 5 
Small cell with equal medium AO fluorescence throughout the cell. 
The bars represent a length of 10 µm
Fig. 7 Representative images of CD45neg cells in abnormal 
CD45neg profiles. a, b Small CD45neg cell (left cell) from donor 9 
under brightfield (a) and AO fluorescence (b, left cell). c–f Large 
CD45neg cells from donor 6. c lymphocyte-like round cell with high 
cytoplasm to nucleus ratio and 14 µm in diameter, d large red bean 
shaped cell with dividing nucleus measuring a horizontal diameter 
of 12.6 µm and vertical diameter of 20 µm, e largest cell with high-
est cytoplasm to nucleus ratio and 21 µm in diameter, f smallest 
abnormal cell measuring 10.8 µm in diameter and lowest cytoplasm 
to nucleus ratio. The bars represent a length of 10 µm
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was found to improve capture efficiency when compared 
to incubation at rest, which we ascribe to increased mag-
netization of the target cell surface. The repetition of 
incubation under rotation (step 2 and 3, Fig.  1) seemed 
to uphold high binding reaction kinetics that would oth-
erwise decline shortly after 1 or 2 min [33]. As a result, a 
relative low bead concentration and amount (bead stock 
estimated to contain 1.4 ×  109 beads per μL) produced 
high magnetically labelled cells within 5 min and allowed 
the use of a simple duopole open gradient magnetic sepa-
rator requiring only 3–5 min of magnetic capture giving 
rise to a 10  min depletion cycle. The enrichment assay 
may lead as fastest high performing assay [27, 29]. Also, 
a simple and efficient in-house magnetic bead system was 
chosen using 100  nm sized beads and targeting directly 
the leukocyte common antigen CD45. In consequence, 
the use of degassed buffers, FcR blocker reagents, addi-
tional primary antibody or linker molecule incubation 
steps or the necessity to prepare magnetic columns was 
obsolete.
Similar to other investigators, repeated depletion cycles 
were applied to achieve ultra-high depletion [27]. How-
ever, our optimization effort went beyond the simple 
concept of repetition for reasons of cost effectiveness 
and high recovery, using different and well-adjusted bead 
amounts at each depletion cycle giving rise to high bead 
efficiency. The averaged bead efficiency of the negative 
selection assay measured 2.6  ×  105 cells/µL beads that 
would correspond to 30- to 40-fold depletion as deter-
mined under test conditions (Fig. 2). Therefore, the split 
into the depletion of high and low reacting leukocytes 
generated a 20-fold improvement in bead efficiency at 
least. The bead efficiency of the second depletion cycle 
measured 6.25  ×  104 cells/µL instead of the expected 
1.4 × 105 cells/µL. One reason was a sixfold increase in 
the debris concentration as a consequence of the incu-
bation volume reduction from 250 to 40 µL between the 
two depletion cycles. Debris such as platelets and RBCs 
would negatively affect bead—cell binding kinetics. Also, 
the initial bead efficiency data arose from cell stocks 
comprising mostly high reacting leukocytes. It shall be 
noted that higher depletion rates would have been pos-
sible by employment of three or more depletion cycles 
however, being on costs of assay time, bead expense and 
recovery that we chose not to pursue. From the quali-
tative analysis by flow cytometry (Fig.  3), we observed 
selective depletion behaviour in favour for larger cell 
types resulting in approximately tenfold higher depletion 
than for what seemed to be smaller lymphocytes. Selec-
tive depletion behaviour was also reported using a similar 
magnetic bead system (anti-CD45, Macs beads) however, 
observing inefficient depletion of the granulocyte frac-
tion [26]. It was theorized that the CD45 receptor on 
granulocytes may present lower affinity than lympho-
cytes and assumed lowered binding affinity of bead con-
jugated anti-CD45, so that lymphocytes would be more 
efficiently labelled. We believe that the cell size was an 
important factor in our system. Larger cells would inter-
act comparatively more frequent with the beads than 
smaller cells hence, being magnetically labelled more 
efficiently.
As much as the requirement on enrichment or deple-
tion factors may vary, a common directive is to minimize 
the loss of cells of interest. During assay evaluation exper-
iments, highest recovery was achieved losing at most 
one cell when spiking 2 cells in 2 out of 3 experiments. 
We carried out several experiments of this kind with the 
conclusion that a greater cell loss had to be ascribed to 
the stickiness of the plastic tubes. Also, previous experi-
mentation revealed insignificant degrees of non-specific 
bead-cell interaction [33]. Un-autoclaved, re-used and 
hand cleaned plastic tubes have been used in two out of 
three 8 cell spike experiments during RBC lysis and cen-
trifugation, and is believed to be the cause of a high cell 
loss relative to the rest of the spiking experiments recov-
ering only 5 out of 8 cells in both cases of mCD45 cells 
(Table 4). This problem was mentioned suggesting to use 
siliconized low-Retention micro-centrifuge tubes [38]. 
Further improvement may be also possible using Protein 
LoBind tubes (Eppendorf AG, Hamburg, Germany).
In line with high recovery, the assay was shown to 
enrich cells without major harm to the cells, as deter-
mined by trypan blue dye staining. The cells do not 
encounter any solid surfaces and shear stress during 
magnetic capture as it would be the case within HGMS 
columns. The results suggested that most harm was done 
by the chemical lysis of RBC, which is in accordance 
with previous work measuring a decrease in viability by 
9–10% [29]. We measured an increase in viability after 
the first depletion cycle by on average 7.5% accounted 
for both mCD45neg cell lines, which could be attributed 
to cell disintegration during centrifugation, non-spe-
cific binding to the plastic tubes and to magnetic beads 
of in particular damaged or dead cells. The viability of 
the second depletion cycle showed a slightly decreased 
viability by on average 2% that would provide an indica-
tion of the level of untouchedness of the negative selec-
tion assay. The cell proliferation capability was somehow 
reduced when compared to the positive control, sug-
gesting underlying cell damage and/or unsuited culture 
conditions in the presence of large amounts of platelets, 
unlysed RBCs and also viable nucleated CD45 positive 
cells (Fig.  4b). It shall be noted that the ovarian cancer 
cell cultures remained unaffected by microbiological con-
tamination throughout the culture period. Comparatively 
little effort was required due to the simple closed system 
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magnetic capture procedure using sterile buffers and pre-
paring samples under laminar flow.
The technical evaluation of bead-based negative selec-
tion assays purposed for the isolation of CD45neg cells 
was deemed important only in a minority of published 
work [27]. We raised the point earlier in the discussion 
that the downstream application determines the perfor-
mance requirements of the CD45neg cell selection assay. 
As a logical consequence, the current situation lacks con-
sensus in the evaluation method of this very specific type 
of assay. Apparently, most applications were devoted to 
the detection and characterization of cancer cells. There-
fore, we propose to benchmark the assay evaluation in 
congruence with the currently accepted reality of CTC 
frequencies at early stage cancer and the requirement of 
a low noise system. In this sense, we suggest to limit the 
range of Ltotal counting 2.5 × 107 to 4 × 107 leukocytes. 
Untreated blood samples should be used for cell spiking 
not exceeding 10 and 100 cells in recovery and cell prolif-
eration experiments, respectively, reporting actual counts 
of recovered cells and proliferative activity. Cell division 
or outgrowth enumeration in reference to a positive con-
trol would possibly allow inter-laboratory comparison. 
To increase accuracy in spiking experiments and prevent 
false positive identification, it is certainly of advantage to 
mark the cells prior to the spiking experiments for later 
undoubted analysis and actively select the cells instead 
of estimating the concentration. Furthermore, we sug-
gest employing at least two cell lines; one is related to the 
downstream application and another one to false positive 
identification.
We considered the isolation of CD45neg cells from 
healthy donor blood samples as a benchmark and the 
evaluation to be complete using the pan-CD45neg cells 
isolation/detection assay. Current literature reports the 
identification of CD45neg cells in healthy donors mostly 
in the specific framework of CTC detection and charac-
terization [38–40]. For that reason, the expected aver-
age number of CD45neg cells in healthy donors remains 
inconclusive for our purpose. CD45neg cells with CTC-
like mutations have been reported in 29.2% in healthy 
donor samples detecting at most 2 cells/3.2 mL PB [41]. 
The cell quantity is comparatively low yet comprehensible 
in view of using the additional FISH markers CEP8 and 
CEP9 beside anti-CD45 and DAPI analysis. The use of a 
similar marker set comprising cytokeratin (CK), CD45, 
DAPI and CEP8 was used in healthy donor blood detect-
ing one CD45neg cell subtype in particular CK negative, 
CD45 negative, DAPI positive and CEP8 positive in 50% 
of the cases with a median of 2 CD45neg cells in range 
of 0–8 cells/3.75  mL whole blood [42]. Abnormal cell 
findings were reported in 93% of healthy donors based 
on morphological and immunologic characteristics with 
a mean of 5.4 cells and a range of 0–22 cells/5 mL [34]. 
However, numbers may not be attributed to exclusively 
CD45neg cells for not explicitly including CD45 cell 
negativity during analysis. Interestingly, this group pre-
sents a seemingly morphologically similar CD45neg cell 
type derived from healthy donors when compared with 
the type 1 cell (Fig. 6) suggesting a frequent but normal 
CD45neg cell type. The detection of medium-sized round 
EpCam neg/CD45neg cells was reported presenting a 
high cytoplasm to nucleus ratio from healthy donors at 
quantities as many as 650 cells/mL whole blood [27]. Also 
in this case, we may find similarities with respect to size, 
roundness, and cytoplasm to nucleus ratio to our finding 
across all sample types (Figs.  5a, 6/type 2, white arrow 
indications). Despite the relative scarcity and the mor-
phological similarity, we identified this cell type as CD45 
positive for presenting lowest CD45PE fluorescence. 
Furthermore, we may exclude the likelihood of complete 
CD45 down regulation caused by the enrichment treat-
ment within given assay time as source of analytical mis-
interpretation. Differential expression of CD45 receptor 
subtypes and consequently the involvement of CD45 was 
reported for events such as cell activation as well as apop-
tosis [43, 44]. Our findings suggest greater morphological 
diversity and quantity of CD45neg cells in healthy donors 
than can be expected from current literature.
We were also interested in the problem of false posi-
tive identification in CTC diagnostics. It was theorized 
that venipuncture would cause contamination by all 
kinds of dermal cells. It has been proposed to discard 
a certain amount of blood as to avoid such contamina-
tion. Our results would not support this assumption 
and instead suggest an increasing loss of CD45neg cells 
with blood resting time. A similar observation of time 
dependent sensitivity has been reported in breast cancer 
experiments [45]. The results may question the common 
practice of initial blood flow discharge and indicate the 
significance to preserve blood samples.
The CD45 exclusion approach during analysis was ini-
tially intended to circumvent problems of cell marker 
usage such as complex multiple marker analysis, the 
assumption of makers and the variation in expression 
level [39], but most of all to obtain a complete picture of 
isolated CD45neg cells. Together with the findings of the 
high CD45neg cell diversity in healthy donors, the idea of 
CD45 exclusion analysis evolved into the concept of pan-
CD45neg cell profiling eligible for the evaluation of the 
health status beyond cancer. We hypothesised that cer-
tain profiles of CD45neg cell subtypes may be indicative 
for various health conditions and await to be determined 
in the future. The findings of three donors that seemed 
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to present abnormal profiles may support our thoughts. 
Donor 2 had a pre-existing blood condition of thrombo-
cytosis (tripled platelet count compared to normal) and a 
relative low RBC count (determined by eye). The CD45neg 
cell profile showed low large and medium sized CD45neg 
cell counts (max. 2 cells) yet many small CD45neg cells 
counting at most 16 cells. It is believed that such cells 
would be nucleated RBCs as determined by morphology 
(Fig.  7a, b). The same type of cells and at elevated lev-
els counting 7 cells was identified in the blood sample of 
donor 9. The blood cells of donor 9 appeared normal in 
regard to RBC, platelet, and leukocyte count. However, 
the donor was reported to be a routine blood donor hav-
ing donated 500 mL 14 days before the donation for this 
study. Both donors were associated with slight anaemic 
conditions assuming the production and elevation of RBC 
precursors (Fig. 7a, b). Donor 9 exclusively had a profile of 
CD45neg cell elevation throughout all cell size groups. We 
can only speculate that this is result of a blood cell regen-
eration process. Donor 6 presented a unique set of large 
CD45neg cells with high as well as very low cytoplasm to 
nucleus ratio (Fig. 7c–f). This donor is currently followed 
up for being in suspicion of an underlying condition.
Conclusion
We presented an in-house enrichment assay based on 
magnetic bead separation technology targeting rare 
CD45neg cells in peripheral blood by depleting normal 
cells. Technological advancements comprised simplic-
ity, assay speed, bead expense and cell loss. We proved 
that highly sophisticated magnetic capture technology 
and lengthy cell separation procedures are avoidable by 
enhancements in magnetic bead labelling of target cells. 
Also, the simplicity of magnet capture system facili-
tated sterile sample preparations. Moreover, the enrich-
ment assay was found to be highly specific yielding near 
complete recovery of spikes cells. As a consequence, 
we detected a wide range of different CD45neg cells in 
healthy donor peripheral blood samples at frequencies 
up to 22 CD45 negative cells/2.5 × 107 nucleated normal 
cells. We addressed the research question of CD45neg cell 
contamination during phlebotomy concluding that such 
contaminations may occur yet seem to be subordinate to 
additional most likely blood circulating CD45 negative 
cells. We concluded that a short resting time of the blood 
sample in range of a few hours was beneficial for the isola-
tion and detection of rare CD45 negative cells. The find-
ing of a great variety of CD45neg cells has led us to the 
concept of CD45 negative profiles. Despite directing the 
assay purpose towards the enrichment and identification 
of CTCs, this concept may have potential to be extended 
to the liquid biopsy for screening of other malignancies 
that are associated with CD45 negative cells.
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